Bleeding News and Research

RSS

Skin cancer patients may benefit from smaller surgical margins

Many skin cancer patients fare just as well when surgeons remove about one inch of normal-looking tissue around the lesion instead of a larger safety margin, according to a new systematic review.

7 Oct 2009

HRT may increase urinary incontinence in postmenopausal women

Grappling with the risks and benefits of hormone replacement therapy (HRT) is nothing new for postmenopausal women. Researchers have now added more fuel to the fire, with evidence that HRT could play a role in incontinence.

7 Oct 2009

Vantia Therapeutics announces the start of Phase II proof-of-concept trials of its VA111913 drug

Vantia Therapeutics today announces that its novel oral small molecule drug for the treatment of dysmenorrhoea (painful menstruation) has entered Phase II proof-of-concept trials. In addition, Vantia announces results of the successful Phase I trial of VA111913, which showed the product candidate to be safe and well tolerated.

6 Oct 2009

Medtronic receives global distribution rights for PEAK Surgical’s tissue dissection device

PEAK Surgical, Inc. and Medtronic, Inc. (NYSE: MDT) today announced an agreement that grants the Surgical Technologies business at Medtronic exclusive rights for global distribution and marketing of the PEAK PlasmaBlade® TnA (Tonsil and Adenoid) tissue dissection device for the ear, nose, and throat (ENT) market.

6 Oct 2009

CSL Behring - Canada Research Chair to develop therapies for treating bleeding and immune system disorders

The Centre for Blood Research (CBR) and the Faculty of Medicine at the University of British Columbia have announced the establishment of the CSL Behring - Canada Research Chair in Endothelial Cell Biology. Over the next five years, the CBR and CSL Behring Canada, the biopharmaceutical company co-funding the chair program, will collaborate on the research and development of new therapies for patients with bleeding and immune system disorders.

5 Oct 2009

Radiofrequency-tonsillotomy: Effective method for treating children with enlarged tonsils

Radiofrequncy-tonsillotomy, which enables surgeons to reduce the size of the tonsillar tissue instead of removing the tonsils entirely, seems to be an effective and safe method of treating children with symptoms of enlarged tonsils.

5 Oct 2009

Researchers engineer antidotes for blood-thinner aptamers

Imagine a surgical patient on a blood-thinning drug who starts bleeding more than expected, and an antidote that works immediately - because the blood thinner and antidote were designed to work together. Researchers at Duke University Medical Center have engineered a way to do this for an entire, versatile class of drugs called aptamers and published their findings in Nature Medicine.

4 Oct 2009

FDA approves Bayer's IUD Mirena for treating heavy menstrual bleeding

The U.S. Food and Drug Administration today approved Mirena (levonorgestrel intrauterine system) to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention. This is the first intrauterine device approved by the FDA for this additional indication.

3 Oct 2009

Aspirin use in seniors study

Researchers at Monash University and the United States-based Berman Center for Outcomes & Clinical Research will lead an international clinical trial to test whether taking aspirin contributes to good health in the elderly.

1 Oct 2009

Study sheds light on why some hospitals have lower mortality than others

A compelling University of Michigan Health System study debunks assumptions about the role of complications in distinguishing good and bad hospitals.

1 Oct 2009

St. Mary Medical Center offers Frameless Stereotactic Radiosurgery treatment to fight cancer

For patients diagnosed with a brain tumor, St. Mary Medical Center is among the first in the region to offer Frameless Stereotactic Radiosurgery (SRS) as a breakthrough treatment to fight cancer. Frameless Stereotactic Radiosurgery is a one-time application of a large-dose radiation precisely targeting a tumor.

1 Oct 2009

Swemed Sense oocyte aspiration needle available now for Australian customers

“Swemed Sense, with its unique characteristics, is an important part of our existing product portfolio in Europe, and is now available even to our Australian customers, Says Vitrolife's Vice President of Marketing and Sales, Nils Sellbom. Vitrolife have identified Australia as one of the key markets in the world and we have a office located in Melbourne. Approximately 67 000 fertility treatment cycles are conducted in Australia and New Zealand each year”

1 Oct 2009

National Institutes of Health awards $16.8 million grant to Hutchinson Center/UW group

The National Heart, Lung and Blood Institute of the National Institutes of Health has awarded a $16.8 million, seven-year grant to launch a bicoastal research partnership between Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium and Children's Hospital of Philadelphia.

30 Sep 2009

New treatment for chronic sinusitis from Summit Ear, Nose & Throat

Summit Ear, Nose & Throat is the first in the area to offer an exciting new treatment for chronic sinusitis (CRS) in an outpatient setting called FinESS™ Sinus Treatment. FinESS is a new balloon sinuplasty technique that is less invasive than traditional sinus surgery and that breaks the cycle of chronic sinusitis with immediate relief and lasting results.

30 Sep 2009

Coupling electrosurgery with mass spectrometry for real-time identification of tumor tissues

Instead of the classic scalpel, surgeons can also operate with an electroscalpel. A significant advantage to this technique is that while a cut is being made, blood vessels are closed off and hemorrhaging eliminated. Now another advantage may be added as well: a German-Hungarian research team has developed a mass-spectrometry-based technique by which tissues can be analyzed during a surgical procedure.

30 Sep 2009

Medtronic launches the Endurant Abdominal Stent Graft System in Canada

Expanding the application of endovascular aortic repair around the world, Medtronic, Inc., announces the launch of the EndurantTM Abdominal Stent Graft System in Canada.

30 Sep 2009

New anticoagulant therapy has fewer side-effects than warfarin

In an article reviewed by F1000 Medicine Faculty Members Robert Ruff, Brian Olshansky and Luis Ruilope, the blood-thinner dabigatran is shown to protect against stroke, blood clotting and major bleeding as effectively as warfarin, but with fewer side effects.

30 Sep 2009

Researchers find new ways to treat Myelodysplastic Syndrome

Van Andel Research Institute (VARI) researchers are one step closer to finding new ways to treat Myelodysplastic Syndrome (MDS), a bone marrow disease that strikes up to 15,000 people each year in the United States, and that sometimes results in acute myeloid leukemia.

30 Sep 2009

Minimally invasive mitral valve surgery is safe and effective

Surgical treatment for mitral valve disease includes either repairing the patient's diseased valve or replacing it with a metal, mechanical valve or an animal tissue valve. The majority of those procedures are open-heart operations that require a major incision in the chest. Now, after a six-year study, surgeons at the University of Maryland Medical Center in Baltimore conclude that minimally invasive mitral valve repair techniques, through only a two-inch incision in the right side of the chest, are safe, durable and effective. The results are published in the September 2009 Annals of Surgery.

29 Sep 2009

HORIZONS-AMI clinical trial demonstrates efficacy of drug-eluting stent

Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.

25 Sep 2009